n e w s a n d v i e w s variation, such as the 1000 Genomes 2 and UK10K (http://www.uk10k.org) Projects.
The study by Holm et al. 1 also highlights the value of focusing on well-characterized sample collections with deep phenotype data. When information on multiple quantitative or dichotomous traits is available, sequencing a representative, carefully-selected subset of the study sample (for example, to maximize imputation efficiency by preferentially targeting distantly related individuals for whole-genome sequencing) can enable downstream association testing for a wide variety of phenotypes. haplotype phasing approaches 3 and established a strong association with a missense variant, c.2161C>T (p.Arg721Trp), in MYH6 (RAF 0.0038, odds ratio (OR) = 12.53). No significant association remained at chromosome 4 after accounting for c.2161C>T. The authors subsequently validated the association by directly typing this variant in the discovery samples and by replicating the association in an independent modestly-sized set of 469 Icelandic cases and 1,185 controls (RAF 0.0021, OR = 12.59). c.2161C>T is not present in the HapMap or 1000 Genomes Project data and was not identified in any of the 1,776 European-descent controls or 135 US cases investigated 1 . The lifetime risk of disease is 50% for c.2161C>T carriers and 6% for noncarriers, and the c.2161C>T sibling recurrence risk ratio (λ s ) for sick sinus syndrome is 1.52, which is substantially higher than most common-frequency risk variants for complex diseases. This variant is likely to be specific to the Icelandic population and is estimated to have arisen approximately 30 generations ago.
The work of Holm et al. 1 illustrates a new and powerful approach for complex trait association studies ( Fig. 1) and is the state of the art, at least until whole-genome sequencing costs enable sequencing of full study samples. For example, simulations 4 suggest that sequencing 200 individuals from an outbred European-descent population at 6× depth can provide near-comprehensive coverage of variants down to MAF 0.01 and ~40% of variants with MAF 0.001-0.01. Imputation approaches can then take advantage of variants discovered within the study sample subset, in conjunction with publicly available reference sets, to infer untyped variants in the full dataset using GWAS data as a scaffold. Indeed, this is one of the key aims of large-scale investments to create repositories of whole-genome sequence Genome-wide association studies (GWAS) of complex traits have been successful in identifying common variant associations, but a substantial heritability gap remains. The field of complex trait genetics is shifting toward the study of low-frequency (minor allele frequency (MAF) 0.01-0.05) and rare (MAF <0.01) variants, which are hypothesized to have larger effects. The study of these variants can be empowered by focusing on isolated populations. On page 316 of this issue, Hilma Holm, Kari Stefansson and colleagues 1 apply an innovative study design ( Fig. 1 ) that combines whole-genome sequence and GWAS data from Icelandic individuals to detect a susceptibility locus for sick sinus syndrome at MYH6, encoding the alpha heavy chain subunit of cardiac myosin. This association is an almost ideal poster child for the type of variants that the field hopes to discover through sequence-based association, with a low population allele frequency (0.1-1%) and a strong effect on disease susceptibility (on the order of tenfold relative risk).
Next-generation study design
Holm et al. 1 first identified a signal comprising multiple low frequency SNPs (risk allele frequency (RAF) 0.01-0.026) on chromosome 14 through GWAS and imputation of 1000 Genomes Project 2 variants into a study sample of 792 individuals with sick sinus syndrome (cases) and 37,585 controls. To refine this association, they performed wholegenome sequencing of 7 cases and 80 controls at a mean depth of 10×. They then imputed 11 million newly discovered variants into the full set of GWAS samples using long-range next-generation association studies for complex traits Eleftheria Zeggini a new study successfully applies complementary whole-genome sequencing and imputation approaches to establish robust disease associations in an isolated population. This strategy is poised to help elucidate the role of variants at the low end of the allele frequency spectrum in the genetic architecture of complex traits. 
the c.2161C>T variant in MYH6, are low-hanging fruit amenable to easy detection through the application of this powerful strategy. The analytical toolset for straightforward single-variant complex-trait association probing can be borrowed from GWAS and adapted to meet truly full-genome scales. The field of statistical genetics is also actively developing more sophisticated methods that consider the aggregation of rare variants within functional units of interest 5 . Incorporation of functional annotation is currently a challenge for interpreting association at variants for which putative consequences are not as readily inferred as for missense variants.
Value of population isolates
Holm et al. 1 have also taken advantage of the increased discovery power afforded by studying a population isolate. Population isolates have well-documented characteristics that can aid in the detection of low frequency and rare variants in complex disorders 6 , namely reduced phenotypic, environmental and genetic heterogeneity. Population bottlenecks and subsequent expansion from a relatively small number of founders can lead to increased genetic homogeneity and a rise in rare variant allele frequency. These characteristics are complemented by elevated levels of linkage disequilibrium, which enable long-range haplotype matching 3 and accurate imputation.
A potential drawback of this approach is the uncertainty of whether or not the findings will generalize to further populations. For example, it remains to be seen whether different variants within MYH6 are associated with sick sinus syndrome outside of Iceland. Nevertheless, the detected association, even if not directly transferrable beyond the study sample population, provides new insights into the biology of this disease. It is widely accepted that one of the main reasons behind decades of unsuccessful candidate gene studies has been poor understanding of the underlying disease etiology, a point clearly illustrated by a host of unexpected GWAS findings. Importantly, to establish the biological underpinnings of pathogenicity, functional studies tailored to the phenotype under study are required.
The work of Holm et al. 1 provides proof of principle for a powerful whole-genome sequencing-based study design that leverages population genetics characteristics of isolates to reduce the number of samples to be sequenced without compromising power. Using cuttingedge high-throughput sequencing technologies and analytical tools, this work ushers in a new era of next-generation genetic studies that will help fill the missing heritability gap for complex traits.
RNA-like molecules in which the ribose moiety is locked by an oxymethylene bridge connecting the C(2´) and C(4´) atoms of the ribose. The result of this linkage is a conformationally constrained molecule that has unusually high duplex melting temperatures and stability. The ability of LNA backbone-modified oligos to form strong hybrids with complementary sequences was the key to the findings of Obad et al. 3 , in which tiny LNAs that are complementary to the miRNA seed sequences potently block miRNA functions (Fig. 1) .
Previously, 15-nucleotide LNA-phosphorothioate antimiRs were effective in blocking the function of miR-122 in a nonhuman primate 10 . Because a 15-mer would target more than the seed sequence, there is the potential for offtarget inhibition of other miRNAs. Thus, Obad et al. 3 investigated the functional consequences of targeting only the seed sequence. They first tested 7-mer and 8-mer LNA antimiRs targeting miR-21, which has elevated levels in a variety of cancers. They found that targeting the seed region with a perfectly matched 8-base antimiR potently inhibited miR-21 function targets 6 . Given the small number of bases required for miRNA function, it is not too surprising that a single miRNA can modulate the expression of several hundred different mRNAs that harbor seed site complementarities in their 3′ untranslated regions 7 . Blocking the function of a single miRNA that is dysregulated can have a major effect on disease progression. This is not a simple task, as there are redundant miRNAs that target the same sequence because they have identical seeds but which differ outside the seed. The solution appears to be selectively inhibiting miRNAs using only the seed as a target. miRNA sponges, transcripts which have multiple seed binding sites, can selectively silence a single species of miRNA by binding the seed, but this approach requires a DNA vector that has to be introduced into all target cells, making it inconvenient as a therapy 8 .
The recent findings of Obad et al. 3 describe a new technique for targeting the seed sequence that appears to have universal applicability. They took advantage of a major breakthrough in antisense oligonucleotide backbone modification termed locked nucleic acids (LNAs) 9 . These are The initial description of miRNAs that modulate the expression of protein-encoding mRNAs created an entirely new paradigm in gene regulation 1 . Defects in specific miRNA expression levels have been linked to disease onset and progression, and loss or gain of miRNA function has been directly linked to various cancers 2 . On page 371 of this issue, a study by Sakari Kauppinen and colleagues 3 describes an important new strategy for silencing the function of miRNAs. Their work capitalizes upon earlier studies, which showed that backbonemodified antisense oligos, called antagomirs or antimiRs, hybridize with and block the function of miRNAs in vitro and in vivo 4, 5 .
The seed is the key Amazingly, only six to eight nucleotides at the 5′ end of the miRNA, termed the 'seed' sequence, are required to identify the appropriate mRNA
